This study aims to evaluate the safety, tolerability and effectiveness of BTA798 on * shortening the length and reducing the symptoms of human rhinovirus infection (also known as the common cold), * controlling asthma symptoms, and * lowering the risk of asthma symptoms worsening in subjects with asthma.
Subjects with a previous diagnosis of asthma will be pre screened within 90 days prior to enrolment. If a subject develops symptoms of human rhinovirus (HRV) infection they will visit the site for assessment. Symptomatic subjects meeting all eligibility criteria will be invited to enroll.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
300
Wisconsin Upper Respiratory Symptom Survey-21 (WURSS-21) Questionnaire
Daily Change in WURSS-21 Severity Score Averaged over Days 2 to 4. The Wisconsin Upper Respiratory Symptom Survey-21 (WURSS-21) Questionnaire is an evaluative illness-specific outcomes instrument designed to assess the severity of cold symptoms and the impact of the common cold (range 0-140), with higher scores indicating more symptoms and functional impairment.
Time frame: Days 2-4
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Research Site
Scottsdale, Arizona, United States
Research Site
Little Rock, Arkansas, United States
Research Site
Fountain Valley, California, United States
Research Site
Orange, California, United States
Research Site
Waterbury, Connecticut, United States
Research Site
Hialeah, Florida, United States
Research Site
Bangor, Maine, United States
Research Site
Baltimore, Maryland, United States
Research Site
Bethesda, Maryland, United States
Research Site
Boston, Massachusetts, United States
...and 33 more locations